#News: This month Celcuity’s CEO and co-founder, Brian Sullivan, will participate in two fireside chats at the upcoming TD Cowen 45th Annual Health Care Conference & Leerink Global Healthcare Conference 2025. Read the full press release here: https://lnkd.in/gK-gdjeX
About us
Celcuity is a clinical-stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth. Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com
- Website
-
https://www.celcuity.com
External link for Celcuity
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Minneapolis, MN
- Type
- Public Company
- Founded
- 2012
Locations
-
Primary
Get directions
16305 36Th Ave N
Minneapolis, MN 55446, US
Employees at Celcuity
Updates
-
#News: Celcuity reports third quarter 2024 financials and provides recent updates: https://lnkd.in/gK-gdjeX A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: https://lnkd.in/e85sCksE #earnings #oncology #biotechnology
-
-
#News: This month Celcuity’s CEO and co-founder, Brian Sullivan, will participate in two fireside chats at the upcoming Stifel 2024 Healthcare Conference & the Jefferies London Healthcare Conference. Read the full press release here: https://lnkd.in/gK-gdjeX #oncology #biotech
-
-
#News: Celcuity schedules the release of third quarter 2024 financial results for Thursday, November 14, 2024 at 4:30 PM ET: https://lnkd.in/gK-gdjeX A live webcast presentation can be accessed using this link: https://lnkd.in/e85sCksE #earnings #oncology
-
-
October is #BreastCancerAwarenessMonth. This month, #Celcuity joins individuals around the world to honor those affected by breast cancer. Our team remains committed to clinically developing our lead drug candidate, gedatolisib, a potential first-in-class targeted therapy to treat advanced breast cancer.
-
-
Today is #NationalMammographyDay. We join others to raise awareness for #breastcancer and the important role mammograms play in the early detection of breast cancer.
-
-
On this #WorldCancerResearchDay, we recognize and celebrate the scientists working effortlessly to develop an effective treatment for patients battling cancer. At Celcuity, our researchers are clinically developing a first-in-class treatment targeting the PI3K /mTOR pathway, which has been implicated in a wide variety of human cancers including carcinomas of the breast, prostate, lung, endometrial, colon, and ovary, among others.
-
-
September is #ProstateCancerAwarenessMonth, #OvarianCancerAwarenessMonth, and #GynecologicalCancerAwarenessMonth. Our team of scientists at Celcuity is committed to advancing our lead candidate, Gedatolisib, designed to address unmet need for patients.
-
-
#News: Celcuity reports second quarter 2024 financials and provides recent updates: https://lnkd.in/gK-gdjeX A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: https://lnkd.in/dfzgn9dQ #earnings #oncology #biotechnology
-
-
#News: Celcuity schedules the release of second quarter 2024 financial results for Wednesday, August 14, 2024 at 4:30 PM ET: https://lnkd.in/gK-gdjeX A live webcast presentation can be accessed using this link: https://lnkd.in/dfzgn9dQ #earnings #oncology #biotechnology
-